Cargando…
Exebacase: A Novel Approach to the Treatment of Staphylococcal Infections
Lysins are bacteriophage-derived enzymes that degrade essential components of bacteria. Exebacase (Lysin CF-301) is an attractive antimicrobial agent because it demonstrates rapid bacteriolytic activity against staphylococcal species, including Staphylococcus aureus, has a low resistance profile, er...
Autor principal: | McCarthy, Matthew W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167414/ https://www.ncbi.nlm.nih.gov/pubmed/35175568 http://dx.doi.org/10.1007/s40268-022-00383-6 |
Ejemplares similares
-
Rapid bacteriolysis of Staphylococcus aureus by lysin exebacase
por: Vila-Farres, Xavier, et al.
Publicado: (2023) -
Development of a Broth Microdilution Method for Exebacase Susceptibility Testing
por: Oh, Jun T., et al.
Publicado: (2021) -
Determination of MIC Quality Control Parameters for Exebacase, a Novel Lysin with Antistaphylococcal Activity
por: Traczewski, Maria M., et al.
Publicado: (2021) -
The treatment of resistant staphylococcal infections
por: John Jr, Joseph
Publicado: (2020) -
The Lysin Exebacase Has a Low Propensity for Resistance Development in Staphylococcus aureus and Suppresses the Emergence of Resistance to Antistaphylococcal Antibiotics
por: Oh, Jun, et al.
Publicado: (2023)